Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Barclays Analyst Says
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its price objective lifted by Barclays from $42.00 to $47.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 13.24% from the company’s current price. A number […]
15 Oct 14:54 · The Markets Daily